在经历了2023年下滑后,复星医药(600196.SH、02196.HK)2024年业绩重新回到增长轨道上。 根据复星医药3月25日披露的财报显示,2024年,公司实现营业收入410.68亿元,同比微跌0.8%,但归属于上市公司股东的净利润为27.7亿元,同比增长16.08%。 在过去的2024年,复星医药进一步聚焦创新药和高值器械业务发展,推进产品结构和策略转型,由此拉动了公司业绩增长。 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.